Fosun Pharmaceutical secured an option to obtain exclusive rights to Aribio’s oral Phase 3 Alzheimer’s disease therapy, AR-1001, in a deal valued at up to $4.7 billion. Fosun will pay $60 million upfront for the option, with additional payments tied to progress under the license. The agreement positions the asset as a major bet in Fosun’s neurodegeneration pipeline, where late-stage risk management and regional rights often determine commercialization upside. Aribio, a Korean biotech, characterized the package as the largest Alzheimer’s deal by a Korean company. For the sector, the transaction reflects persistent competition for late-stage CNS assets, even as the industry continues to scrutinize evidence quality and trial success rates.